Au­rinia faces chop­py wa­ters amid low­er-than-ex­pect­ed 2022 guid­ance and patent chal­lenge on Lup­ky­nis

A new patent chal­lenge to Au­rinia Phar­ma­ceu­ti­cals’ lu­pus nephri­tis drug Lup­ky­nis is adding to the bio­phar­ma’s woes this week. Sun Phar­ma­ceu­ti­cal is chal­leng­ing Au­rinia’s “treat­ment pro­to­col” patent, the com­pa­ny re­vealed in a 10-K fil­ing this week first re­port­ed by STAT.

Au­rinia pushed back on the news re­port, point­ing out, in a state­ment to End­points News, that the patent has al­ready been through “sig­nif­i­cant re­view” with the US Patent and Trade­mark Of­fice be­fore Lup­ky­nis was ap­proved by the FDA in Jan­u­ary 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER